Abbott’s Panbio Rapid Antigen Test Receives CE Mark for Mass COVID-19 Screening
AbbVie Enters into a Collaboration to Develop Monoclonal Antibody Therapy for Preventing COVID-19
AbbVie Enters into a Collaboration to Develop Monoclonal Antibody Therapy for Preventing COVID-19
Shots:
- AbbVie collaborated with Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) to develop a novel Ab to prevent and treat COVID-19. The collaboration focuses on advancing 47D11, discovered by UU, EMC and HBM that targets the domain of the spike protein of SARS-CoV-2
- AbbVie will support UU, EMC, and HBM in preclinical activities, while simultaneously preparing late-stage pre/ clinical development. AbbVie to get an option to exclusively license the Ab from the three parties for WW clinical development and commercialization
- The Ab discovered by UU, EMC, and HBM is based on the mechanism by which it targets the virus and on its developability as a fully human protein. The is designed to facilitate its development and minimize immune-related side effects
Click here to read full press release/ article | Ref: AbbVie | Image: AbbVie